What type of study is this?

December 8, 2025BloodOpen Access

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows efficacy and lower cytokine release syndrome rates with low pre-lymphodepletion plasma cell burden in multiple myeloma.

Patients with low pre-lymphodepletion plasma cell burden had higher efficacy rates with cilta-cel, achieving greater responses.
Notably, lower rates of cytokine release syndrome were associated with low plasma cell burden prior to treatment, improving overall safety.
Findings from the International Myeloma Working Group highlight the importance of bridging therapy in treatment protocols.
High efficacy rates and reduced neurotoxicity were observed, emphasizing the role of biochemical response and bridging therapy.

Avila et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows efficacy and lower cytokine release syndrome rates with low pre-lymphodepletion plasma cell burden in multiple myeloma.

Patients with low pre-lymphodepletion plasma cell burden had higher efficacy rates with cilta-cel, achieving greater responses.
Notably, lower rates of cytokine release syndrome were associated with low plasma cell burden prior to treatment, improving overall safety.
Findings from the International Myeloma Working Group highlight the importance of bridging therapy in treatment protocols.
High efficacy rates and reduced neurotoxicity were observed, emphasizing the role of biochemical response and bridging therapy.

Avila et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark